You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

  1. CORPORATE - 10-01-2018

    Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

    Goal is to improve access to replacement therapies for coagulation disorders in Europe

    read more 

  2. CORPORATE - 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells

    read more 

  3. CORPORATE - 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 

  4. CORPORATE - 19-04-2017

    Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)

    The agreement aims to improve patient access to coagulation disorders treatments in Europe

    read more 

Pages

For more information please contact: pressoffice@kedrion.com